Thomson Scientific Launches Thomson Innovation

The Thomson CorporationThomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, has launched its new intellectual property research and analysis solution, Thomson Innovation. For the first time, researchers will be able to simultaneously search worldwide editorially enhanced patent data, Asian patent data translated into English, scientific literature, and business and news sources.

"The global intellectual property market is changing rapidly, and organizations need to be aware of changes in the evolving landscape, such as the proliferation of patenting activity in Asia," said David Brown, Executive Vice President, Corporate Markets, Thomson Scientific. "It's more critical than ever for our customers to have access to the most authoritative patent data, and to incorporate complementary sources, like scientific literature, in their intellectual property research."

Designed in collaboration with more than 1,800 customers, Thomson Innovation sets a new standard in intellectual property research and analysis that will help companies accelerate ideation, improve productivity, minimize risks and gain a competitive advantage. It provides:

  • Comprehensive prior art searching with the ability to search patents and scientific literature simultaneously
  • Expanded Asian patent coverage, including translations of Japanese full-text and additional editorially enhanced abstracts of Chinese data
  • A fully integrated searchable database combining Derwent World Patent Index® (DWPISM) with full-text patent data to provide the most comprehensive patent records available
  • Support of strategic intellectual property decisions through:
    • powerful analysis and visualization tools, such as charting, citation mapping and search result ranking
    • and, integration of business and news resources
  • Enhanced collaboration capabilities, including customizable folder structures that enable users to organize, annotate, search and share relevant files

Thomson Innovation is being launched in phases, and the first release is available now and includes global, full-text patent sources, including Japan. In rapid succession, it will be followed by the addition of Derwent World Patents Index, scientific literature, business information and news. A series of additional enhancements will be delivered throughout 2008.

For more information about Thomson Innovation, visit www.thomsoninnovation.com.

About The Thomson Corporation
The Thomson Corporation is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation’s common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC). Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development—from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at http://scientific.thomson.com.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...